{"id":39254,"date":"2026-07-30T09:58:00","date_gmt":"2026-07-30T13:58:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/ultragenyx-pharmaceutical-inc-v-navinta-llc\/"},"modified":"2026-06-17T04:15:11","modified_gmt":"2026-06-17T08:15:11","slug":"ultragenyx-pharmaceutical-inc-v-navinta-llc","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/ultragenyx-pharmaceutical-inc-v-navinta-llc\/","title":{"rendered":"ULTRAGENYX PHARMACEUTICAL INC. v. NAVINTA LLC"},"content":{"rendered":"<h2><strong>Ultragenyx Pharma v. Navinta 2:26-cv-03585: Litigation Summary, Claims, and Business Impact<\/strong><\/h2>\n<p><strong>Executive summary:<\/strong> The case <strong>Ultragenyx Pharmaceutical Inc. v. Navinta LLC, No. 2:26-cv-03585 (filed 2026)<\/strong> is a patent infringement dispute tied to generic or biosimilar-style market entry pressures. The docket number indicates a federal IP case in the District of New Jersey. <strong>A complete litigation summary (claims, asserted patents, procedures, and status) cannot be produced from the information provided.<\/strong>  <\/p>\n<h2><strong>What patents are asserted in Ultragenyx Pharma v. Navinta LLC 2:26-cv-03585?<\/strong><\/h2>\n<p>A litigation summary depends on the asserted patent list contained in the <strong>complaint<\/strong>, <strong>initial disclosures<\/strong>, or <strong>early scheduling orders<\/strong>. With only the case caption and docket number provided, the asserted patents, assignees, and claim numbers are not determinable.<\/p>\n<h3><strong>Which patent numbers are listed in the complaint<\/strong><\/h3>\n<ul>\n<li>Not available from the provided input.<\/li>\n<\/ul>\n<h3><strong>Are the asserted patents Orange Book listed patents or other IP<\/strong><\/h3>\n<ul>\n<li>Not available from the provided input.<\/li>\n<\/ul>\n<h2><strong>What is the procedural posture in 2:26-cv-03585 (filed, answered, Markman, injunction, discovery)?<\/strong><\/h2>\n<p>A credible posture requires docket events and dates (e.g., <strong>Rule 16\u2026<\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>Ultragenyx Pharma v. Navinta 2:26-cv-03585: Litigation Summary, Claims, and Business Impact Executive summary: The case Ultragenyx Pharmaceutical Inc. v. Navinta [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":34556,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-39254","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39254","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=39254"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39254\/revisions"}],"predecessor-version":[{"id":39380,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39254\/revisions\/39380"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/34556"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=39254"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=39254"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=39254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}